Skip to main content
OpenTrials
Completed

NCT Number: NCT03265899

Oxytocin and the Processing of Social Stress-Associated Chemosignals

The purpose of this study is to determine whether oxytocin modulates the processing of stress-associated chemosignals and which substrates are involved.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

About this study

Social transmission of stress and fear is not restricted to visual or auditory cues, but extends to the olfactory domain, a phylogenetically more ancient sense. Exposure to axillary sweat from healthy volunteers undergoing an emotional stressor task evokes a strong vicarious stress response on the behavioral and neural level.Particularly, anxious individuals have been shown to exhibit a heightened sensitivity to social chemosensory stress cues (axillary sweat). The neuropeptide oxytocin (OXT) exerts anxiolytic and anti-stress effects in visual and auditory modalities, however, it still elusive whether OXT also modulates the processing of stress-associated chemosignals. Axillary sweat were obtained from an unrelated sample of 30 healthy men undergoing the Trier Social Stress Test and ergometer training as control.Subsequently, subjects completed a forced-choice emotional face recognition task composed of stimuli with varying intensities (neutral to fearful), while they were exposed to both sweat stimuli and a non-social control odor (raspberry) after OXT or placebo administration, respectively. The investigators expect that OXT selectively diminishes chemosensory-induced behavioral biases and neural responses to stress-related odors.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy volunteers
  • Right-handed

Exclusion criteria

  • Current or past psychiatric disease
  • Current or past physical illness
  • Psychoactive medication
  • Tobacco smokers
  • MRI contraindications (e.g. metal in body, claustrophobia)
  • Anosmia
  • Medication known to interfere with olfactory processing

Treatment and study plan

Oxytocin

Drug

40 IU; 5 puffs balanced across nostrils, at an inter-puff interval of 30 seconds

Other names: Syntocinon-Spray, Novartis

Placebo

Drug

Placebo nasal spray, 5 puffs balanced across nostrils, at an inter-puff interval of 30 seconds

Other names: Placebo-Spray, Novartis

Primary outcomes

  1. Forced-choice ratings of morphed emotional faces with varying intensities (neutral to fearful).

    Time frame: 30 min after nasal spray administration

    After each trial, subjects were asked to use a button response grip to indicate whether they perceived the depicted face as neutral or fearful.

  2. Response time for facial stimuli ratings.

    Time frame: 30 min after nasal spray administration

  3. Blood-oxygen-level dependent signal in response to chemosensory cues.

    Time frame: 30 minutes after nasal spray administration

    The modulatory effect of oxytocin on neural correlates Using functional magnetic resonance imaging, signal changes in the amygdala, hippocampus and the anterior cingulate cortex in response to olfactory cues of stress and sport (axillary sweat obtained from an unrelated sample of 30 healthy men undergoing the Trier Social Stress Test and ergometer training as control).

Secondary outcomes

  1. Questionnaire measurement of mood (PANAS).

    Time frame: 15 minutes before the nasal spray administration and (on average) 10 minutes after the fMRI experiment

  2. Saliva oxytocin concentrations

    Time frame: immediately before the nasal spray administration and (on average) 10 minutes after the fMRI experiment

  3. Questionnaire measurement of anxiety (STAI).

    Time frame: 15 minutes after nasal spray administration and (on average) 10 minutes after the fMRI experiment

Sponsors and collaborators

Lead sponsor

University Hospital, Bonn

Other

Registry information

Official study title

Double-blind, Placebo-controlled, Randomized Study: Oxytocin Modulation of Stress-Associated Chemosignals Processing

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Aug 29, 2017
Registry last updated
Aug 29, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.